Ligand Pharmaceuticals, Inc. (LGND)
289.74
+2.82
(+0.98%)
USD |
NASDAQ |
Sep 03, 16:00
289.34
-0.40
(-0.14%)
After-Hours: 20:00
Ligand Pharmaceuticals Cash from Investing (Quarterly) : 321.12M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 321.12M |
| March 31, 2026 | -94.35M |
| December 31, 2025 | -18.10M |
| September 30, 2025 | -353.44M |
| June 30, 2025 | -10.67M |
| March 31, 2025 | 4.894M |
| December 31, 2024 | -38.62M |
| September 30, 2024 | -46.51M |
| June 30, 2024 | -54.76M |
| March 31, 2024 | -3.775M |
| December 31, 2023 | -10.28M |
| September 30, 2023 | -19.50M |
| June 30, 2023 | 7.556M |
| March 31, 2023 | 10.55M |
| December 31, 2022 | -7.284M |
| September 30, 2022 | 19.18M |
| June 30, 2022 | 37.85M |
| March 31, 2022 | 113.88M |
| December 31, 2021 | -35.71M |
| September 30, 2021 | -18.22M |
| June 30, 2021 | 19.34M |
| March 31, 2021 | 65.12M |
| December 31, 2020 | -382.20M |
| September 30, 2020 | 332.07M |
| June 30, 2020 | -26.76M |
| Date | Value |
|---|---|
| March 31, 2020 | 308.54M |
| December 31, 2019 | -63.18M |
| September 30, 2019 | 169.52M |
| June 30, 2019 | 265.80M |
| March 31, 2019 | 94.78M |
| December 31, 2018 | 275.30M |
| September 30, 2018 | -78.25M |
| June 30, 2018 | -586.74M |
| March 31, 2018 | -33.58M |
| December 31, 2017 | -41.17M |
| September 30, 2017 | -56.54M |
| June 30, 2017 | 44.20M |
| March 31, 2017 | -30.67M |
| December 31, 2016 | -86.73M |
| September 30, 2016 | 5.078M |
| June 30, 2016 | 18.22M |
| March 31, 2016 | -79.76M |
| December 31, 2015 | -11.48M |
| September 30, 2015 | -26.36M |
| June 30, 2015 | -72.22M |
| March 31, 2015 | -2.797M |
| December 31, 2014 | -1.711M |
| September 30, 2014 | 0.072M |
| June 30, 2014 | 0.61M |
| March 31, 2014 | -0.998M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -1.11B |
| Eli Lilly & Co. | -15.40B |
| Merck & Co., Inc. | -5.602B |
| Zevra Therapeutics, Inc. | 31.45M |
| Liquidia Corp. | -12.24M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 24.02M |
| Cash from Financing (Quarterly) | 546.43M |
| Free Cash Flow | 119.83M |
| Free Cash Flow Per Share (Quarterly) | 0.9778 |
| Free Cash Flow to Equity (Quarterly) | -658.12M |
| Free Cash Flow to Firm (Quarterly) | 22.67M |
| Free Cash Flow Yield | 1.98% |